The pharma intelligence platform market looks fundamentally different in 2026 than it did three years ago. Database subscriptions that defined the category for two decades are no longer the default choice for CI, BD, and NPP teams evaluating their intelligence stack. AI workflow platforms have entered the market and the question has shifted from "which database has the best coverage" to "which platform closes the gap between data and finished deliverable."
This guide assesses the leading pharma intelligence platforms honestly — what each does well, where each falls short, and which use cases each serves best.
Five years ago, the pharma intelligence stack was relatively simple: a Cortellis subscription for clinical and regulatory data, a GlobalData or EvaluatePharma subscription for pipeline and commercial data, and a consulting firm or in-house team to synthesise it into deliverables.
Two structural shifts have disrupted that model. First, deal and intelligence velocity has accelerated — quarterly database refresh cycles are structurally incompatible with intelligence needs that move at the speed of the market. Second, generative AI has made synthesis automatable for the first time, but only through platforms built specifically for life sciences, not generic AI tools adapted from financial services.
FERMA — Best for: CI, BD&L, NPP, Medical Affairs, and Portfolio Strategy teams that need finished deliverables
Ferma is an AI-powered life sciences intelligence platform that delivers finished strategic deliverables through 12+ pre-built Agentic Workflows. Built by ZoomRx, a 500-person life sciences consultancy trusted by 19 of the top 20 global pharma firms. Strengths: continuously updated data, finished deliverable output, native China pipeline coverage, conference coverage built in (489,000 records, 250+ conferences), asset-level data organisation, full auditability.
Limitations: newer market entrant, REST API on roadmap. Best use case: teams spending 40%+ of analyst time on data reconciliation and formatting.
CORTELLIS (CLARIVATE) — Best for: Teams needing structured clinical and regulatory data feeds
Strengths: comprehensive structured database, broad TA coverage, established regulatory filing tracking, API access for data infrastructure.
Limitations: periodic updates, event-organised data model requiring manual reconciliation, no synthesis layer, no conference coverage, limited China pipeline. Best use case: data engineering teams building internal intelligence infrastructure who need a structured data feed.
ALPHASENSE — Best for: Document search and earnings call intelligence
Strengths: strong AI search capability, good earnings call and investor report coverage, real-time financial intelligence. Limitations: built for financial services, uneven life sciences data coverage, particularly in preclinical intelligence, China pipeline, and conference data. Returns search results rather than finished deliverables. Best use case: commercial and market access teams needing earnings call and investor report search.
GLOBALDATA & EVALUATEPHARMA — Best for: TA overviews, epidemiology, and commercial pipeline data
Strengths: wide TA coverage, strong epidemiology and market sizing data, useful for initial indication scoping.
Limitations: periodic exports updated quarterly at best, limited AI workflow integration, no conference coverage, limited China pipeline. Best use case: NPP and portfolio teams doing initial indication scoping who need broad TA overviews.
LARVOL — Best for: Pre-conference session prioritisation
Strengths: fast, affordable, well-designed for pre-congress planning, strong oncology conference focus.
Limitations: stops at planning — no live session coverage, no AI-generated post-congress summaries, no synthesis layer. Best use case: CI and Medical Affairs teams that need session prioritisation for oncology congresses.
The right platform depends on where your team's intelligence bottleneck sits.
If your bottleneck is data access — Cortellis or GlobalData/EvaluatePharma solve the problem.
If your bottleneck is synthesis — your team spends more than two days assembling a competitive landscape — Ferma closes the gap.
If your bottleneck is conference coverage — you're getting summaries 48+ hours after the session — Ferma's native conference Agentic Workflow addresses it end to end.
If your bottleneck is China pipeline visibility — native NMPA monitoring narrows the field significantly. This is a genuine differentiator in 2026, not a standard feature.
The most important distinction in the 2026 pharma intelligence market isn't between individual platforms. It's between two categories: database subscriptions that give you data to work with, and AI workflow platforms that give you finished intelligence to act on.
For teams whose primary constraint is analyst capacity, the category distinction matters more than any individual feature comparison. A database subscription with better coverage doesn't solve a synthesis bottleneck. An AI workflow platform purpose-built for life sciences does.
The best pharma intelligence platform for your team is the one that solves the right bottleneck.
Ferma is trusted by 19 of the top 20 global pharma firms. See which Agentic Workflows are right for your team.